Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: July 20, 2023
Event: Authorization of a new share repurchase program.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data disclosed relates to capital allocation:
- New Share Repurchase Authorization: Up to $500 million.
- Prior Program Completion: The company completed the repurchase of $650 million under the prior program on June 5, 2023.
Material Changes
The Board of Directors authorized a new share repurchase program on July 20, 2023, which supersedes the prior program approved in November 2017, July 2020, and July 2022. The new program grants management discretionary authority to repurchase shares on the open market or through privately negotiated transactions.
Guidance, Outlook, and Management Commentary
Program Terms:
- The program has no time limit.
- It may be suspended or discontinued at any time.
- Acquired shares will be held for general corporate purposes, including supporting employee stock plans, funding acquisitions, and minimizing dilution from stock issuances.
Investor Verification Checklist
- Verify the exact number of shares repurchased under the new $500 million program in subsequent filings.
- Confirm the impact of the $650 million prior program completion on the company's cash balance and liquidity position.
- Monitor future 8-K filings for any suspension or discontinuation of the new repurchase program.
- Review the attached press release (Exhibit 99.1) for additional management commentary not included in the 8-K text.